EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische StudieOpen Access · CC BY 4.0

Efficacy and safety of carmustine wafers, followed by radiation, temozolomide, and bevacizumab therapy, for newly diagnosed glioblastoma with maximal resection

Masayuki Kanamori, Ichiyo Shibahara, Yoshiteru Shimoda, Yukinori Akiyama, Takaaki Beppu, Shigeo Ohba, Toshiyuki Enomoto, Takahiro Ono, Yuta Mitobe, Mitsuto Hanihara, Yohei Mineharu, Joji Ishida und 20 weitere

International Journal of Clinical Oncology · 2025-01 · 30 (1) · 51-61

DOI: 10.1007/s10147-024-02650-9 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift International Journal of Clinical Oncology, online erschienen am 11.11.2024. Verfasst von Masayuki Kanamori und 31 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Tohoku University Graduate School of Medicine, Sendai, Japan. mkanamori@med.tohoku.ac.jp. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Bevacizumab, Brain Neoplasms, Carmustine. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Funds for this study were provided by Eisai, Co., Ltd..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

To improve the outcome in newly diagnosed glioblastoma patients with maximal resection, we aimed to evaluate the efficacy and safety of implantation of carmustine wafers (CWs), radiation concomitant with temozolomide and bevacizumab, and maintenance chemotherapy with six cycles of temozolomide and bevacizumab.

Method

This prospective phase II study enrolled glioblastoma patients considered candidates for complete resection (> 90%) of a contrast-enhanced lesion. The CWs were intraoperatively implanted into the resection cavity after achieving maximal resection. Patients without a measurable contrast-enhanced lesion on magnetic resonance imaging within 48 h after resection received concomitant radiotherapy and chemotherapy with temozolomide and bevacizumab, followed by maintenance treatment with up to six cycles of temozolomide and bevacizumab. The primary endpoint was the 2-year overall survival rate in glioblastoma patients with protocol treatment.

Results

From October 2015 to April 2018, we obtained consent for the first registration from 70 patients across 17 institutions in Japan, and 49 patients were treated according to the protocol. We evaluated the safety in 49 patients who were part of the second registration and the efficacy in 45 glioblastoma patients treated according to the protocol. The profile of hematological and most of the non-hematological adverse effects was similar to that in previous studies, but stroke occurred in 12% of cases (6/49 patients). The estimated 2-year overall survival rate was 51.3%.

Conclusion

Implantation of CWs, followed by concomitant radiation, temozolomide, and bevacizumab, and six cycles of temozolomide and bevacizumab may offer some benefit to survival in Japanese glioblastoma patients with maximal resection. Trial ID jRCTs021180007.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsBevacizumabBrain NeoplasmsCarmustineChemoradiotherapyGlioblastomaTemozolomideAdultAgedFemaleHumansMaleMiddle AgedMagnetic Resonance ImagingProspective StudiesSurvival RateTreatment Outcome

Stichwörter der Autor:innen

BevacizumabCarmustine wafersGlioblastomaMaximal resectionTemozolomide

Substanzen

BevacizumabCarmustineTemozolomide

Autor:innen und Institutionen

  • Department of Neurosurgery, Tohoku University Graduate School of Medicine, Sendai, Japan. mkanamori@med.tohoku.ac.jp.
  • Department of Neurosurgery, Kitasato University School of Medicine, Sagamihara, Japan.
  • Department of Neurosurgery, Tohoku University Graduate School of Medicine, Sendai, Japan.
  • Department of Neurosurgery, Sapporo Medical University School of Medicine, Sapporo, Japan.
  • Department of Neurosurgery, Iwate Medical University, Shiwa, Japan.
  • Department of Neurosurgery, Fujita Health University, Toyoake, Japan.

Förderung

  • Funds for this study were provided by Eisai, Co., Ltd.

Zitieren

APA

Kanamori, M., Shibahara, I., Shimoda, Y., Akiyama, Y., Beppu, T., Ohba, S., Enomoto, T., Ono, T., Mitobe, Y., Hanihara, M., Mineharu, Y., Ishida, J., Asano, K., Yoshida, Y., Natsumeda, M., Nomura, S., Abe, T., Yonezawa, H., Katakura, R., …, & Tominaga, T. (2025). Efficacy and safety of carmustine wafers, followed by radiation, temozolomide, and bevacizumab therapy, for newly diagnosed glioblastoma with maximal resection. International Journal of Clinical Oncology, 30(1), 51-61. https://doi.org/10.1007/s10147-024-02650-9

Vancouver

Kanamori M, Shibahara I, Shimoda Y, Akiyama Y, Beppu T, Ohba S, et al. Efficacy and safety of carmustine wafers, followed by radiation, temozolomide, and bevacizumab therapy, for newly diagnosed glioblastoma with maximal resection. International Journal of Clinical Oncology. 2025;30(1):51-61. doi:10.1007/s10147-024-02650-9

BibTeX
@article{Kanamori2025,
  author = {Kanamori, Masayuki and Shibahara, Ichiyo and Shimoda, Yoshiteru and Akiyama, Yukinori and Beppu, Takaaki and Ohba, Shigeo and Enomoto, Toshiyuki and Ono, Takahiro and Mitobe, Yuta and Hanihara, Mitsuto and Mineharu, Yohei and Ishida, Joji and Asano, Kenichiro and Yoshida, Yasuyuki and Natsumeda, Manabu and Nomura, Sadahiro and Abe, Tatsuya and Yonezawa, Hajime and Katakura, Ryuichi and Shibui, Soichiro and Kuroiwa, Toshihiko and Suzuki, Hiroyoshi and Takei, Hidehiro and Matsushita, Haruo and Saito, Ryuta and Arakawa, Yoshiki and Sonoda, Yukihiko and Hirose, Yuichi and Kumabe, Toshihiro and Yamaguchi, Takuhiro and Endo, Hidenori and Tominaga, Teiji},
  title = {Efficacy and safety of carmustine wafers, followed by radiation, temozolomide, and bevacizumab therapy, for newly diagnosed glioblastoma with maximal resection},
  journal = {International Journal of Clinical Oncology},
  year = {2025},
  volume = {30},
  number = {1},
  pages = {51--61},
  doi = {10.1007/s10147-024-02650-9}
}
Kostenlos starten →